Bupivacaine is frequently used to provide intra-operative analgesia for children, and is especially popular because of the prolonged pain relief it affords in the postoperative period. Reports of central nervous system toxicity at plasma concentrations greater than 4 mg/p,2,3 have, however, led to conservative dosage recommendations. In Australia, the manufacturer's recommended maximum dose is 2 mg/kg. The aim of the present study was to determine plasma levels of bupivacaine occurring after doses of 2 and 3 mg/kg to children via axillary brachial plexus shock. Previous studies of bupivacaine in children have been limited to subcutaneous 4 or caudaI 4 ,5,6 routes of administration.
MATERIALS AND METHODS

Patients
The patients studied were undergoing emergency or elective orthopaedic or plastic surgery. The protocol was approved by the Ethics Committee of the Princess Margaret Hospital for Children. Informed consent was obtained from the parents prior to surgery. Premedication was most commonly pethidine and atropine (27 patients), with seven receiving omnopon and scopolamine, four diazepam and three no premedication. General anaesthesia was induced with thiopentone, prior to axillary block, and was usually maintained with nitrous oxide/oxygen and narcotic/relaxant technique. Plexus block was performed with a 23 ga scalp vein needle in children less than 25 kg, and with a 22 ga Terumo short bevel needle with extension tubing in larger children. The needles were inserted with the bevel parallel to the longitudinal axis of the brachial sheath, anterior to the axillary artery. Aftt:r aspiration, injection was completed over 60-90 sec with 3-5 pauses for aspiration during this period. Subsequent success of the block was invariably indicated by the development of a 'sausagelike' distension of the brachial sheath which was easily palpable.
Study design
The first twenty-one patients received a dose of 2 mg/kg bupivacaine (0.6 mllkg of 0.33070 plain bupivacaine). When the data from the first patient group were complete, and it had been ascertained that venous plasma levels were safe (vide infra), a second group of 20 patients was then studied using a dose of 3 mg/kg (0.6 mllkg of 0.5% plain bupivacaine). The volume of local anaesthetic solution used was that recommended to achieve total blockade of the brachial plexus. 7 Venous blood samples (each 2 ml) were taken from the contralateral arm, mostly using the cephalic vein at the wrist. Samples were taken immediately prior to the block and then at 0.5, 5, 10, 15, 20, 25, 35, 45 and 60 minutes after administration of the drug. Blood was collected into heparinised tubes, and after centrifugation, plasma was removed and stored at -20°C for subsequent measurement of bupivacaine concentration.
Analysis of bupivacaine by high-performance liquid chromatography
Aliquots of plasma (0.5 ml) were mixed with internal standard (0.6 I1g disopyramide hydrochloride in 50 111 water), alkalinised with 100 111 0.5M NaOH and extracted with 10 ml ethyl acetate:hexane:methanol (60:40:0.4) by shaking for 5 minutes. After centrifugation at 1500 G for 5 minutes, 9 ml of the organic layer was removed to a clean tube and evaporated to dryness under a stream of nitrogen at 45°C. The residue was redissolved by briefly sonicating with 50 ~ of acetonitrile, followed by the addition of 150 ~ KH2P04 buffer (pH 3.8). Aliquots (50 111 each) were injected onto the column.
Analysis was carried out using a Waters 6000A pump, Model 441 fixed wavelength detector, U6K injector and a u Bondapak CI8 column (30 cm x 4.6 mm i.d.). The mobile phase of 26% acetonitrile in 0.03M, pH 3.8 KH2P04 buffer was pumped at a flow rate of 1.5 mllmin. and peaks were detected by their ultra-violet absorbance at 214 nm (0.02 a.u.f.s.). Under these conditions, disopyramide and bupivacaine chromatograph with approximate retention times of 6.3 and 10 minutes respectively. The plot of peak height ratio (bupivacaine: internal standard) was linear up to 3000 I1g/1 and the assay had a lower detection limit of detection of 10 I1g/l. The within day coefficient of variation was 2.9 and 1.4% at 56 and 2800 I1g/1 respectively (n = 5) while the between day coefficient of variation was 3.4% at 280 I1g/1 (n = 20) and 2.1 % at 2100 I1g/1 (n = 9). A range of other drugs administered to the patients during or before the operation was tested and found not to interfere in the assay procedure.
Data analysis
Data were summarised as mean concentrations with standard deviations and differences between means were assessed by Student's Hest. Sex distribution between the two groups of patients was compared by a Chisquared test. Area under the plasma concentration-time curve (0-1 h) was calculated by the linear trapezoidal rule. The characteristics of the patients are summarised in Table 1 . There were no significant differences in sex distribution, age or body weight between the two groups of patients. Efficacy of neural blockade was assessed by lack of response to surgical stimulus and lack of pain in the recovery room. All patients had adequate sensory blockade. In general, those who were given the 2 mg/kg dose had partial motor blockade, while those who had the 3 mg/kg dose had complete motor blockade. The children were visited in the ward the day following surgery and no neurologic sequelae were apparent. time at which the peak occurred were noted for each patient and these data appear in Table 2 . Peak concentration in the 3 mg/kg dose group was significantly higher than for the 2 mg/kg group (t = 3.74, P<O.OOl) but the time of peak was similar for both groups. Area under the plasma concentration-time curve was also significantly greater (t = 3.15, P<0.005) at the higher dose. The highest individual plasma concentration of 2.73 mg/l and also the highest area under the plasma-time curve occurred in a patient who received 3 mg/kg.
DISCUSSION
In this study venous plasma concentrations of bupivacaine were studied since arterial sampling was considered too invasive a procedure. However, the relationship between arterial and venous concentrations of bupivacaine is well documented.
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ID After caudaI,5 supraclavicular IO or intercostal 9 blocks, arterial plasma bupivacaine levels in the first 20-30 minutes after dose are 5, 9 and 300/0 higher respectively than corresponding venous concentrations. Even if arterial concentrations in our patients had been 30% higher than corresponding venous concentrations, our mean peak arterial concentrations would have ranged from approximately 1.8 to 2.4 mg/l, and the highest individual peak arterial level would have been about 3.5 mg/I. These concentrations are below the arterial concentrations at which toxicity is considered likely (>4 mg/I).1.2.3 In a study of 5th cranial nerve and cervical plexus blocks for head and neck surgery, an average dose of 3.4 mg/kg bupivacaine resulted in a mean peak venous plasma level of 4.95 mg/I. 11 The highest individual concentration was 6 mg/I. These blocks were performed under general anaesthesia and no clinical signs of toxicity were apparent. In a study of intravenous infusions of bupivacaine in conscious volunteers, single peak plasma arterial concentrations of 7.5 and 22.5 mg/l were recorded without overt toxicity, although subjective feelings of circumoral numbness and dizziness were experienced. 12 We consider, therefore, that doses of 2 or 3 mg/kg for axillary plexus block in children result in venous plasma concentrations which are unlikely to produce toxicity. However, great care should be taken to avoid intravascular injection during administration of the block, given the proximity of the axillary artery and vein.
Compared with caudal block in children 4 • 5 venous plasma concentrations of bupivacaine in our study using axillary block were higher after both the 2 mg/kg (0.75 mg/l for caudal versus 1.35 mg/l for axillary) and 3 mg/kg doses (1.27 mg/l for caudal versus 1.84 mg/l for axillary). This is probably a reflection of the greater vascularity of the axillary compared to the caudal site of injection. In adults, one study of eight patients who received 2 mg/kg bupivacaine with adrenaline via the axillary route resulted in a mean venous plasma concentration of 0.82 mg/l.13 Another study in seven adults who received 3 mg/kg axillary bupivacaine reported a mean venous concentration of 1.44 mg/l. 14 Absorption of bupivacaine was very rapid at both the 2 and 3 mg/kg doses and this observation is consistent with the high lipid solubility of the drug l5 and the vascularity of the axillary injection site. Because of the relatively short sampling time (l hour) which was predetermined by the nature of the surgical procedures involved, it was not possible to obtain meaningful estimates of the pharmacokinetic parameters characterising the disposition of bupivacaine in our patients. . -The advantage of being able to use 3 mg/kg bupivacaine via the axillary block is seen particularly in plastic surgery, where the motor blockade produced by 0.5070 bupivacaine is of considerable benefit during and after tendon transfers and cross finger flaps. The larger dose of bupivacaine is also useful where combined nerve blocks are desirable; for example, with skin grafts to the arm, combination of femoral and lateral cutaneous nerve blocks for the donor site, with axillary block for the graft site results in marked improvement in analgesia in the postoperative period. Additionally, when free radial flaps from the forearm are applied to the leg, combination of axillary and caudal or sciatic blocks results in improved operating . conditions (vasodilation), as well as postoperative analgesia. Being able to use a total dose of 3 mg/kg of bupivacaine greatly increases the efficacy of multiple nerve block.
